It was therefore not possible to conduct heterogeneity analyses to test whether healthcare expenditures were particularly high among standard of care group participants with potential opportunistic infections and CD4 counts close to (but above) the treatment cutoffs. This evidence concerns the gene CD4 and Opportunistic infection.